-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Treatment -X- _ O
with -X- _ O
ipilimumab -X- _ B-Patient
, -X- _ O
a -X- _ O
fully -X- _ O
human -X- _ O
anti-CTLA-4 -X- _ O
antibody -X- _ O
approved -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
advanced -X- _ O
melanoma -X- _ O
, -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
some -X- _ O
immune-related -X- _ O
adverse -X- _ O
events -X- _ O
( -X- _ O
irAEs -X- _ O
) -X- _ O
such -X- _ O
as -X- _ O
colitis -X- _ B-Intervention
( -X- _ I-Intervention
gastrointestinal -X- _ I-Intervention
irAE -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
GI -X- _ I-Intervention
irAE -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ O
skin -X- _ O
rash -X- _ O
, -X- _ O
which -X- _ O
are -X- _ O
managed -X- _ O
by -X- _ O
treatment -X- _ O
guidelines. -X- _ O
Nevertheless -X- _ O
, -X- _ O
predictive -X- _ B-Outcome
biomarkers -X- _ I-Outcome
that -X- _ O
can -X- _ O
help -X- _ O
identify -X- _ O
patients -X- _ O
more -X- _ O
likely -X- _ O
to -X- _ O
develop -X- _ O
these -X- _ O
irAEs -X- _ B-Intervention
could -X- _ O
enhance -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
these -X- _ O
toxicities. -X- _ O
METHODS -X- _ O
: -X- _ O
To -X- _ O
identify -X- _ O
candidate -X- _ B-Outcome
predictive -X- _ I-Outcome
biomarkers -X- _ I-Outcome
associated -X- _ O
with -X- _ O
GI -X- _ B-Intervention
irAEs -X- _ I-Intervention
, -X- _ O
gene -X- _ O
expression -X- _ O
profiling -X- _ O
was -X- _ O
performed -X- _ O
on -X- _ O
whole -X- _ O
blood -X- _ O
samples -X- _ O
from -X- _ O
162 -X- _ B-Patient
advanced -X- _ I-Patient
melanoma -X- _ I-Patient
patients -X- _ I-Patient
at -X- _ I-Patient
baseline -X- _ I-Patient
, -X- _ I-Patient
3 -X- _ I-Patient
and -X- _ I-Patient
11 -X- _ I-Patient
weeks -X- _ I-Patient
after -X- _ I-Patient
the -X- _ I-Patient
start -X- _ I-Patient
of -X- _ I-Patient
ipilimumab -X- _ I-Patient
treatment -X- _ I-Patient
in -X- _ I-Patient
two -X- _ I-Patient
phase -X- _ I-Patient
II -X- _ I-Patient
clinical -X- _ I-Patient
trials -X- _ I-Patient
( -X- _ O
CA184004 -X- _ O
and -X- _ O
CA184007 -X- _ O
) -X- _ O
. -X- _ O
Overall -X- _ O
, -X- _ O
49 -X- _ O
patients -X- _ O
developed -X- _ O
Grade -X- _ O
2 -X- _ O
or -X- _ O
higher -X- _ O
( -X- _ O
grade -X- _ O
2+ -X- _ O
) -X- _ O
GI -X- _ B-Intervention
irAEs -X- _ I-Intervention
during -X- _ O
the -X- _ O
course -X- _ O
of -X- _ O
treatment. -X- _ O
A -X- _ O
repeated -X- _ O
measures -X- _ O
analysis -X- _ O
of -X- _ O
variance -X- _ O
( -X- _ O
ANOVA -X- _ O
) -X- _ O
was -X- _ O
used -X- _ O
to -X- _ O
evaluate -X- _ O
the -X- _ O
differences -X- _ O
in -X- _ O
mean -X- _ O
expression -X- _ O
levels -X- _ O
between -X- _ O
the -X- _ O
GI -X- _ B-Intervention
irAE -X- _ I-Intervention
and -X- _ O
No-GI -X- _ B-Comparison
irAE -X- _ I-Comparison
groups -X- _ I-Comparison
of -X- _ I-Comparison
patients -X- _ I-Comparison
at -X- _ O
the -X- _ O
three -X- _ O
time -X- _ O
points. -X- _ O
RESULTS -X- _ O
: -X- _ O
In -X- _ B-Outcome
baseline -X- _ I-Outcome
samples -X- _ I-Outcome
, -X- _ I-Outcome
27 -X- _ I-Outcome
probe -X- _ I-Outcome
sets -X- _ I-Outcome
showed -X- _ I-Outcome
differential -X- _ I-Outcome
mean -X- _ I-Outcome
expression -X- _ I-Outcome
( -X- _ I-Outcome
≥ -X- _ I-Outcome
1.5 -X- _ I-Outcome
fold -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
≤ -X- _ I-Outcome
0.05 -X- _ I-Outcome
) -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
GI -X- _ I-Outcome
irAE -X- _ I-Outcome
and -X- _ I-Outcome
No-GI -X- _ I-Outcome
irAE -X- _ I-Outcome
groups. -X- _ I-Outcome
Most -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
probe -X- _ I-Outcome
sets -X- _ I-Outcome
belonged -X- _ I-Outcome
to -X- _ I-Outcome
three -X- _ I-Outcome
functional -X- _ I-Outcome
categories -X- _ I-Outcome
: -X- _ I-Outcome
immune -X- _ I-Outcome
system -X- _ I-Outcome
, -X- _ I-Outcome
cell -X- _ I-Outcome
cycle -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
intracellular -X- _ I-Outcome
trafficking. -X- _ I-Outcome
Changes -X- _ I-Outcome
in -X- _ I-Outcome
gene -X- _ I-Outcome
expression -X- _ I-Outcome
over -X- _ I-Outcome
time -X- _ I-Outcome
were -X- _ I-Outcome
also -X- _ I-Outcome
characterized. -X- _ I-Outcome
In -X- _ I-Outcome
the -X- _ I-Outcome
GI -X- _ I-Outcome
irAE -X- _ I-Outcome
group -X- _ I-Outcome
, -X- _ I-Outcome
58 -X- _ I-Outcome
and -X- _ I-Outcome
247 -X- _ I-Outcome
probe -X- _ I-Outcome
sets -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
≥ -X- _ I-Outcome
1.5 -X- _ I-Outcome
fold -X- _ I-Outcome
change -X- _ I-Outcome
in -X- _ I-Outcome
expression -X- _ I-Outcome
from -X- _ I-Outcome
baseline -X- _ I-Outcome
to -X- _ I-Outcome
3 -X- _ I-Outcome
and -X- _ I-Outcome
11 -X- _ I-Outcome
weeks -X- _ I-Outcome
after -X- _ I-Outcome
first -X- _ I-Outcome
ipilimumab -X- _ I-Outcome
dose -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
In -X- _ I-Outcome
particular -X- _ I-Outcome
, -X- _ I-Outcome
on-treatment -X- _ I-Outcome
expression -X- _ I-Outcome
increases -X- _ I-Outcome
of -X- _ I-Outcome
CD177 -X- _ I-Outcome
and -X- _ I-Outcome
CEACAM1 -X- _ I-Outcome
, -X- _ I-Outcome
two -X- _ I-Outcome
neutrophil-activation -X- _ I-Outcome
markers -X- _ I-Outcome
, -X- _ I-Outcome
were -X- _ I-Outcome
closely -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
GI -X- _ I-Outcome
irAEs -X- _ I-Outcome
, -X- _ I-Outcome
suggesting -X- _ I-Outcome
a -X- _ I-Outcome
possible -X- _ I-Outcome
role -X- _ I-Outcome
of -X- _ I-Outcome
neutrophils -X- _ I-Outcome
in -X- _ I-Outcome
ipilimumab-associated -X- _ I-Outcome
GI -X- _ I-Outcome
irAEs. -X- _ I-Outcome
In -X- _ I-Outcome
addition -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
several -X- _ I-Outcome
immunoglobulin -X- _ I-Outcome
genes -X- _ I-Outcome
increased -X- _ I-Outcome
over -X- _ I-Outcome
time -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
greater -X- _ I-Outcome
increases -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
grade -X- _ I-Outcome
2+ -X- _ I-Outcome
GI -X- _ I-Outcome
irAEs. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Gene -X- _ B-Outcome
expression -X- _ I-Outcome
profiling -X- _ I-Outcome
of -X- _ I-Outcome
peripheral -X- _ I-Outcome
blood -X- _ I-Outcome
, -X- _ I-Outcome
sampled -X- _ I-Outcome
before -X- _ I-Outcome
or -X- _ I-Outcome
early -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
course -X- _ I-Outcome
of -X- _ I-Outcome
treatment -X- _ I-Outcome
with -X- _ I-Outcome
ipilimumab -X- _ I-Outcome
, -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
identification -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
set -X- _ I-Outcome
of -X- _ I-Outcome
potential -X- _ I-Outcome
biomarkers -X- _ I-Outcome
that -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
occurrence -X- _ I-Outcome
of -X- _ I-Outcome
GI -X- _ I-Outcome
irAEs. -X- _ I-Outcome
However -X- _ I-Outcome
, -X- _ I-Outcome
because -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
low -X- _ I-Outcome
sensitivity -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
biomarkers -X- _ I-Outcome
, -X- _ I-Outcome
they -X- _ I-Outcome
can -X- _ I-Outcome
not -X- _ I-Outcome
be -X- _ I-Outcome
used -X- _ I-Outcome
alone -X- _ I-Outcome
to -X- _ I-Outcome
predict -X- _ I-Outcome
which -X- _ I-Outcome
patients -X- _ I-Outcome
will -X- _ I-Outcome
develop -X- _ I-Outcome
GI -X- _ I-Outcome
irAEs. -X- _ I-Outcome
Further -X- _ O
investigation -X- _ O
of -X- _ O
these -X- _ O
biomarkers -X- _ O
in -X- _ O
a -X- _ O
larger -X- _ O
patient -X- _ O
cohort -X- _ O
is -X- _ O
warranted -X- _ O
. -X- _ O

